HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PQRI

This article was originally published in The Tan Sheet

Executive Summary

International Pharmaceutical Aerosol Consortium will collaborate with Product Quality Research Institute on issues concerning chemistry, manufacturing and control requirements for oral and nasal inhalation products, institute reps announce at Dec. 12 briefing marking PQRI's one-year anniversary. Institute also is considering an FDA request to examine drug counterfeiting issues and expects to make recommendations to agency next year on changes in blend uniformity testing requirements. PQRI is a joint effort between industry, academia and FDA to conduct research that generates scientific support for regulatory policy (1"The Tan Sheet" Oct. 11, 1999, p. 9)

You may also be interested in...



PQRI Working Group To Study Necessity Of Blend Uniformity Testing

The Product Quality Research Institute is recruiting volunteers for a working group that will examine whether blend uniformity testing ensures end product quality, FDA and industry officials announced at the Consumer Healthcare Products Association's Manufacturing Controls Seminar in Philadelphia Oct. 7.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS132855

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel